Market
What level of side effects will be identified in CAR-T therapy for lupus by end of 2025?
2
Resolution / Starting Odds
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
Published results in peer-reviewed medical journals or official safety reports
Story
CAR-T Therapy Shows Promise for Lupus Amid Serious Side Effects
Nov 30, 2024, 01:46 PM
Chimeric Antigen Receptor T-cell (CAR-T) therapy, initially approved for certain blood cancers, is showing promise in early tests for treating autoimmune diseases such as lupus. This innovative therapy is designed to eliminate entire classes of immune cells, potentially addressing conditions like lupus. However, the treatment poses risks of serious side effects. Researchers are also exploring other gene and immune therapies, including a universal gene therapy for Diamond-Blackfan anemia, which aims to correct the disorder regardless of the patient’s specific mutation. Additionally, a drug approved for heart failure has demonstrated potential in killing aggressive ovarian cancer cells and resensitizing relapsed tumors to chemotherapy in preclinical studies. These advancements highlight significant progress in the use of gene and immune-based treatments for various diseases.
View original story
Similar markets
More than 4 • 25%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
Successful with minor safety issues • 25%
Unsuccessful due to safety issues • 25%
Inconclusive results • 25%
Successful with no safety issues • 25%
Positive safety and immunogenicity results • 25%
Negative safety results • 25%
Negative immunogenicity results • 25%
Study inconclusive • 25%
No • 50%
Yes • 50%
Approved in US • 25%
Not approved • 25%
Approved in EU • 25%
Approved in both • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Unsuccessful • 25%
Ongoing • 25%
Successful with FDA approval • 25%
Successful without FDA approval • 25%
FDA approval • 25%
Phase II trial completion • 25%
No significant milestone • 25%
Phase III trial initiation • 25%
Effective but not safe • 25%
Safe but not effective • 25%
Safe and effective • 25%
Neither safe nor effective • 25%
More than 70% • 25%
Less than 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%